Topic

Markets: latest medical news

Pharma, biotech and medtech stock-moving news: earnings, FDA-decision moves, M&A, IPOs and big trial readouts. Figures are quoted from sources only. Not investment advice.

Not investment advice. Market items report news and figures exactly as published by the linked source. Nothing here is a recommendation to buy, sell or hold any security; do your own research or consult a licensed adviser.

1. Saturday, October 24, 2026

   Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

   Source: BioPharma Dive

   In a landmark melanoma study, the Moderna/Merck personalized cancer vaccine (intismeran) plus Keytruda cut the risk of relapse or death by 42%, a result that met Wall Street expectations but triggered a 'sell-the-news' share drop.

   Why it mattersThis is a key test of individualized mRNA cancer vaccines in the adjuvant setting; oncologists will want the full ESMO data, and regulators a first look at a new class with its own manufacturing and safety questions.

2. Saturday, October 24, 2026

   Gilead to pay $1.275B upfront for PepStar's oral IL-23 program

   Source: Fierce Biotech

   Gilead agreed to acquire global rights to Shanghai-based PepStar Therapeutics' oral IL-23 receptor inhibitor program, including phase 1 candidate HCXT-2001, for $1.275 billion upfront, positioning it against J&J's oral Icotyde.

   Why it mattersA large upfront for a phase 1 asset shows how hotly contested oral IL-23 blockade is in inflammatory bowel disease; Gilead says HCXT-2001 could pair with its α4β7 inhibitor emvistegrast for an all-oral combination. Not investment advice.

3. Saturday, October 24, 2026

   Genmab shares rise after Rina-S hits PFS and OS in phase 3 ovarian cancer trial

   Source: RTTNews

   Genmab shares gained about 10% on Friday after the phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer met its primary progression-free survival endpoint and key secondary overall survival endpoint, per RTTNews; Genmab reported a 71% reduction in risk of progression or death and 57% reduction in risk of death versus investigator's-choice chemotherapy.

   Why it mattersPlatinum-resistant ovarian cancer has few effective options, and an OS benefit for an FRα-targeted ADC is a strong regulatory and commercial signal; Genmab plans to discuss the data with regulators. Not investment advice.

4. Saturday, October 24, 2026

   EQT agrees to take diagnostics maker Qiagen private in ~$12.1B deal

   Source: TheBench.Bio

   EQT Private Equity agreed to acquire Qiagen for €46.50 per share in cash, valuing the company at about €10.8 billion ($12.1 billion) including debt; the companies expect the deal to close in mid-2027, subject to shareholder acceptance and regulatory clearances.

   Why it mattersOne of the year's biggest diagnostics and life-science tools take-privates; Qiagen's boards said private ownership could support longer-term investment. Not investment advice.